As one of the most fundamental and widely used devices in modern‑day healthcare, subcutaneous injection needles boast a large‑scale market with steady growth momentum. According to research by Hengzhou Chengsi, the global market size of disposable medical subcutaneous injection needles reached approximately CNY 14.04 billion in 2024, and is projected to approach CNY 20.55 billion by 2031, representing a compound annual growth rate (CAGR) of 5.6% over the next six years. Another report estimates that the global market for disposable subcutaneous injection needles stood at USD 7.985 billion in 2024 and is expected to reach USD 11.238 billion by 2031 at a CAGR of 5.2%. Major drivers of market growth include the rising global prevalence of chronic diseases, growing volume of surgical procedures, widespread vaccination coverage, and surging demand for home‑based healthcare services. Furthermore, growing emphasis on safe injection practices and infection control has fueled the extensive adoption of single‑use safety injection needles.

In terms of market structure, the subcutaneous injection needle industry features high concentration and specialisation, with the global market primarily dominated by several international medical device giants. Industry reports identify leading players as follows: US‑based BD (Becton, Dickinson and Company), Cardinal Health and Smiths Medical; Japan‑based Terumo Corporation and Nipro Corporation; Germany‑based B. Braun Melsungen AG; and Denmark‑based Novo Nordisk (specialising in insulin injection). These companies capture major market shares by virtue of robust R&D capabilities, globalised manufacturing footprints and well‑established sales networks.

BD: Global Leader in Injection Devices

BD is among the world's largest manufacturers of syringes and needles, offering a full product portfolio ranging from standard subcutaneous injection needles to high‑end safety injection devices. It invests heavily in safe injection technologies, with product designs engineered to minimise the risk of needlestick injuries among healthcare workers and comply with increasingly stringent global occupational safety regulations.

Terumo Corporation: Market Leader in Asia

As one of Asia's largest medical device enterprises, Terumo holds notable advantages in subcutaneous injection needles, especially insulin pen needles and blood‑collection needles. The company prioritises product comfort and precision, and its ultra‑fine and ultra‑short needle technologies are highly favoured by diabetic patients. Terumo operates multiple production bases worldwide to ensure supply chain stability.

Nipro Corporation: Focus on Manufacturing and Cost Advantages

Nipro, another major Japanese manufacturer, is renowned for large‑scale, high‑efficiency production capacity and rigorous cost control. With manufacturing plants in Japan, Thailand, China, India, Indonesia, Brazil and other regions, it produces a wide range of products including subcutaneous injection needles, insulin needles and blood‑collection needles. Committed to automated production and strict quality management systems, Nipro delivers cost‑effective and reliable injection needle products.

B. Braun Melsungen AG: European‑Grade Quality and System‑Oriented Solutions

Germany‑based B. Braun not only supplies high‑quality subcutaneous injection needles but also emphasises compatibility and systematic integration with syringes, infusion systems and other products. It has accumulated profound technical expertise in safe injection and drug delivery systems, maintaining a solid market position particularly among European hospitals.

Beyond these global giants, domestic Chinese manufacturers are emerging rapidly and playing an increasingly important role in the global supply chain. For instance, Yangzhou Medelai Medical Products Co., Ltd. specialises in safety injection products, and its needlestick‑proof syringes account for approximately 30% of the US market, demonstrating strong international competitiveness. Zhejiang Beipu Medical Technology Co., Ltd. focuses on niche segments such as insulin pen needles; its "Hummingbird Needle", characterised by ultra‑fine gauge, high rigidity and minimal pain, has gained market recognition.

Going forward, three key trends will shape the market. First, safety‑centric development: injection needles equipped with active or passive safety mechanisms will become standard in hospital settings. Second, greater comfort and personalisation: demand for ultra‑fine, ultra‑short and low‑resistance needles for long‑term users such as diabetic patients will continue to rise. Third, intelligent innovation: smart insulin pen needles integrated with digital medical devices may emerge as a new growth driver. Competition in the global subcutaneous injection needle market is shifting from pure price‑ and scale‑based rivalry to all‑round competition centred on technology, safety, user experience and integrated solutions.